{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:09:17Z","timestamp":1782335357590,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007354","name":"Yen Tjing Ling Medical Foundation","doi-asserted-by":"publisher","award":["CI-110-29"],"award-info":[{"award-number":["CI-110-29"]}],"id":[{"id":"10.13039\/501100007354","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Use of combinations of long-acting \u03b2<jats:sub>2<\/jats:sub> agonists\/long-acting muscarinic antagonists (LABA\/LAMA) in patients with chronic obstructive pulmonary disease (COPD) is increasing. Nevertheless, existing evidence on cardiovascular risk associated with LABA\/LAMA versus another dual combination, LABA\/inhaled corticosteroids (ICS), was limited and discrepant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The present cohort study aimed to examine comparative cardiovascular safety of LABA\/LAMA and LABA\/ICS with a target trial emulation framework, focusing on dual fixed-dose combination (FDC) therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified patients with COPD who initiated LABA\/LAMA FDC or LABA\/ICS FDC from a nationwide Taiwanese database during 2017\u20132020. The outcome of interest was a hospitalized composite cardiovascular events of acute myocardial infarction, unstable angina, heart failure, cardiac dysrhythmia, and ischemic stroke. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for composite and individual cardiovascular events after matching up to five LABA\/LAMA FDC initiators to one LABA\/ICS FDC initiator using propensity scores (PS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 75,926 PS-matched patients, use of LABA\/LAMA FDC did not show a higher cardiovascular risk compared to use of LABA\/ICS FDC, with a HR of 0.89 (95% CI, 0.78\u20131.01) for the composite events, 0.80 (95% CI, 0.61\u20131.05) for acute myocardial infarction, 1.48 (95% CI, 0.68\u20133.25) for unstable angina, 1.00 (95% CI, 0.80\u20131.24) for congestive heart failure, 0.62 (95% CI, 0.37\u20131.05) for cardiac dysrhythmia, and 0.82 (95% CI, 0.66\u20131.02) for ischemic stroke. The results did not vary substantially in several pre-specified sensitivity and subgroup analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings provide important reassurance about comparative cardiovascular safety of LABA\/LAMA FDC treatment among patients with COPD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-023-02545-9","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T16:02:04Z","timestamp":1696003324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative cardiovascular safety of LABA\/LAMA FDC versus LABA\/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework"],"prefix":"10.1186","volume":"24","author":[{"given":"Chun-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Kumamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaa-Hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"2545_CR1","unstructured":"World Health Organization. Global health estimates: life expectancy and leading causes of death and disability 2019. https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates Accessed 26 Feb 2023."},{"key":"2545_CR2","unstructured":"Taiwan Ministry of Health and Welfare. 2020 Cause of death statistics. https:\/\/www.mohw.gov.tw\/lp-5256-2.html. Accessed 26 Feb 2023."},{"key":"2545_CR3","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Diseases. 2023 Report. https:\/\/goldcopd.org\/2023-gold-report-2\/ Accessed 26 Feb 2023."},{"key":"2545_CR4","first-page":"24","volume":"237","author":"CK Billington","year":"2017","unstructured":"Billington CK, Penn RB, Hall IP. \u03b22 agonists. Handb Exp Pharmacol. 2017;237:24\u201340.","journal-title":"Handb Exp Pharmacol"},{"key":"2545_CR5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/164_2016_68","volume":"237","author":"MG Matera","year":"2017","unstructured":"Matera MG, Cazzola M. Muscarinic receptor antagonists. Handb Exp Pharmacol. 2017;237:41\u201362.","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"2545_CR6","doi-asserted-by":"crossref","first-page":"2200302","DOI":"10.1183\/13993003.00302-2022","volume":"61","author":"M Yang","year":"2023","unstructured":"Yang M, Li Y, Jiang Y, Guo S, He JQ, Sin DD. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. Eur Respir J. 2023;61(2):2200302.","journal-title":"Eur Respir J"},{"issue":"11","key":"2545_CR7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/1060028017719716","volume":"51","author":"JC Samp","year":"2017","unstructured":"Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. Risk of cardiovascular and cerebrovascular events in COPD patients treated with long-acting \u03b22-agonist combined with a long-acting muscarinic or inhaled corticosteroid. Ann Pharmacother. 2017;51(11):945\u201353.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2545_CR8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.chest.2021.05.025","volume":"160","author":"MT Wang","year":"2021","unstructured":"Wang MT, Lai JH, Huang YL, Liou JT, Cheng SH, Lin CW, et al. Comparative effectiveness and safety of different types of inhaled long-acting \u03b22-agonist plus inhaled long-acting muscarinic antagonist vs inhaled long-acting \u03b22-agonist plus inhaled corticosteroid fixed-dose combinations in COPD: a propensity score-inverse probability of treatment weighting cohort study. Chest. 2021;160(4):1255\u201370.","journal-title":"Chest"},{"issue":"23","key":"2545_CR9","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. FLAME investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222\u201334.","journal-title":"N Engl J Med."},{"issue":"18","key":"2545_CR10","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. IMPACT investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med."},{"issue":"1","key":"2545_CR11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. ETHOS investigators. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med."},{"issue":"18","key":"2545_CR12","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMe1716802","volume":"378","author":"S Suissa","year":"2018","unstructured":"Suissa S, Drazen JM. Making sense of triple inhaled therapy for COPD. N Engl J Med. 2018;378(18):1723\u20134.","journal-title":"N Engl J Med"},{"issue":"6","key":"2545_CR13","doi-asserted-by":"crossref","first-page":"1801848","DOI":"10.1183\/13993003.01848-2018","volume":"52","author":"S Suissa","year":"2018","unstructured":"Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. Eur Respir J. 2018;52(6):1801848.","journal-title":"Eur Respir J"},{"key":"2545_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2018.08.001","volume":"143","author":"L Parkin","year":"2018","unstructured":"Parkin L, Khuu W, Stanbrook MB, Tadrous M, Martins D, Gomes T. Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA\/LABA combination products: a population-based study. Respir Med. 2018;143:1\u20137.","journal-title":"Respir Med"},{"key":"2545_CR15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2147\/COPD.S393392","volume":"18","author":"PA Liao","year":"2023","unstructured":"Liao PA, Pan SW, Chen CY, Deng CY, Dong YH. Prescription patterns of new use of fixed-dose combination inhalers in patients with chronic obstructive pulmonary disease: long-acting \u03b22 agonists plus long-acting muscarinic antagonists versus long-acting \u03b22 agonists plus inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2023;18:553\u201363.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2545_CR16","unstructured":"National Health Insurance Administration. 2022\u20132023 National Health Insurance Annual Report. https:\/\/www.nhi.gov.tw\/Content_List.aspx?n=9223A12B5B31CB37&topn=4864A82710DE35ED Accessed 26 Feb 2023."},{"key":"2545_CR17","volume":"40","author":"LY Lin","year":"2018","unstructured":"Lin LY, Warren-Gash C, Smeeth L, Chen PC. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health. 2018;40: e2018062.","journal-title":"Epidemiol Health"},{"issue":"8","key":"2545_CR18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"issue":"15","key":"2545_CR19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMp2113319","volume":"385","author":"MA Hern\u00e1n","year":"2021","unstructured":"Hern\u00e1n MA. Methods of public health research\u2014strengthening causal inference from observational data. N Engl J Med. 2021;385(15):1345\u20138.","journal-title":"N Engl J Med"},{"issue":"24","key":"2545_CR20","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference from observational data. JAMA. 2022;328(24):2446\u20137.","journal-title":"JAMA"},{"issue":"16","key":"2545_CR21","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jama.2023.4221","volume":"329","author":"SV Wang","year":"2023","unstructured":"Wang SV, Schneeweiss S. RCT-Duplicate Initiative. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA. 2023;329(16):1376\u201385.","journal-title":"JAMA"},{"issue":"6","key":"2545_CR22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M18-3079","volume":"170","author":"S Schneeweiss","year":"2019","unstructured":"Schneeweiss S, Rassen JA, Brown JS, Rothman KJ, Happe L, Arlett P, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398\u2013406.","journal-title":"Ann Intern Med"},{"key":"2545_CR23","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/dom.14741","volume":"24","author":"YH Dong","year":"2022","unstructured":"Dong YH, Chang CH, Lin JW, Yang WS, Wu LC, Toh S. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Diabetes Obes Metab. 2022;24:1623\u201337.","journal-title":"Diabetes Obes Metab"},{"key":"2545_CR24","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.2147\/COPD.S323391","volume":"16","author":"SH Sun","year":"2021","unstructured":"Sun SH, Chang CH, Zhan ZW, Chang WH, Chen YA, Dong YH. Risk of COPD exacerbations associated with statins versus fibrates: a new user, active comparison, and high-dimensional propensity score matched cohort study. Int J Chron Obstruct Pulmon Dis. 2021;16:2721\u201333.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"2545_CR25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/15412550903140865","volume":"6","author":"AS Gershon","year":"2009","unstructured":"Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. COPD. 2009;6(5):388\u201394.","journal-title":"COPD"},{"issue":"6","key":"2545_CR26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2188\/jea.JE20140076","volume":"24","author":"CL Cheng","year":"2014","unstructured":"Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J Epidemiol. 2014;24(6):500\u20137.","journal-title":"J Epidemiol"},{"issue":"6","key":"2545_CR27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002862","volume":"3","author":"PM Coloma","year":"2013","unstructured":"Coloma PM, Valkhoff VE, Mazzaglia G, Nielsson MS, Pedersen L, Molokhia M, et al. Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open. 2013;3(6): e002862.","journal-title":"BMJ Open"},{"issue":"8","key":"2545_CR28","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/pds.1619","volume":"17","author":"C Varas-Lorenzo","year":"2008","unstructured":"Varas-Lorenzo C, Castellsague J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoepidemiol Drug Saf. 2008;17(8):842\u201352.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"2545_CR29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012832","volume":"6","author":"J Sundb\u00f8ll","year":"2016","unstructured":"Sundb\u00f8ll J, Adelborg K, Munch T, Fr\u00f8slev T, S\u00f8rensen HT, B\u00f8tker HE, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open. 2016;6(11): e012832.","journal-title":"BMJ Open"},{"issue":"7","key":"2545_CR30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218919","volume":"14","author":"F Cozzolino","year":"2019","unstructured":"Cozzolino F, Montedori A, Abraha I, Eusebi P, Grisci C, Heymann AJ, et al. A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases The Umbria Data-Value Project. PLoS ONE. 2019;14(7): e0218919.","journal-title":"PLoS ONE"},{"issue":"2","key":"2545_CR31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pds.4690","volume":"28","author":"P Bosco-L\u00e9vy","year":"2019","unstructured":"Bosco-L\u00e9vy P, Duret S, Picard F, Dos Santos P, Puymirat E, Gilleron V, et al. Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative database. Pharmacoepidemiol Drug Saf. 2019;28(2):194\u2013200.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2545_CR32","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/pds.1869","volume":"19","author":"S Hennessy","year":"2010","unstructured":"Hennessy S, Leonard CE, Freeman CP, Deo R, Newcomb C, Kimmel SE, et al. Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf. 2010;19(6):555\u201362.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"2545_CR33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2125.2008.03249.x","volume":"66","author":"S Hennessy","year":"2008","unstructured":"Hennessy S, Leonard CE, Newcomb C, Kimmel SE, Bilker WB. Cisapride and ventricular arrhythmia. Br J Clin Pharmacol. 2008;66(3):375\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2545_CR34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","volume":"114","author":"CY Hsieh","year":"2015","unstructured":"Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2015;114(3):254\u20139.","journal-title":"J Formos Med Assoc"},{"key":"2545_CR35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2147\/CLEP.S273853","volume":"12","author":"MT Hsieh","year":"2020","unstructured":"Hsieh MT, Hsieh CY, Tsai TT, Wang YC, Sung SF. Performance of ICD-10-CM diagnosis codes for identifying acute ischemic stroke in a National Health Insurance claims database. Clin Epidemiol. 2020;12:1007\u201313.","journal-title":"Clin Epidemiol"},{"key":"2545_CR36","first-page":"CD012066","volume":"2","author":"N Horita","year":"2017","unstructured":"Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2:CD012066.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2545_CR37","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.chest.2019.03.005","volume":"155","author":"S Suissa","year":"2019","unstructured":"Suissa S, Dell\u2019Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest. 2019;155(6):1158\u201365.","journal-title":"Chest"},{"key":"2545_CR38","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jamainternmed.2020.4192","volume":"180","author":"YH Dong","year":"2020","unstructured":"Dong YH, Chang CH, Wang JL, Wu LC, Lin JW, Toh S. Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med. 2020;180:1587\u201395.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2545_CR39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10654-022-00856-7","volume":"37","author":"Z Yang","year":"2022","unstructured":"Yang Z, Toh S, Li X, Edwards D, Brayne C, Mant J. Statin use is associated with lower risk of dementia in stroke patients: a community-based cohort study with inverse probability weighted marginal structural model analysis. Eur J Epidemiol. 2022;37(6):615\u201327.","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"2545_CR40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.annepidem.2013.02.005","volume":"23","author":"J Drahos","year":"2013","unstructured":"Drahos J, Vanwormer JJ, Greenlee RT, Landgren O, Koshiol J. Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data. Ann Epidemiol. 2013;23(5):291\u20133.","journal-title":"Ann Epidemiol"},{"key":"2545_CR41","unstructured":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA. The nearest-neighbor matching algorithm in the Pharmacoepidemiology Toolbox. http:\/\/www.drugepi.org\/dope-downloads\/. Accessed 26 Feb 2023."},{"issue":"3","key":"2545_CR42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivariate Behav Res"},{"key":"2545_CR43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"27","key":"2545_CR44","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391\u2013400.","journal-title":"Stat Med"},{"issue":"4","key":"2545_CR45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512\u201322.","journal-title":"Epidemiology"},{"issue":"2","key":"2545_CR46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/pds.5566","volume":"32","author":"JA Rassen","year":"2023","unstructured":"Rassen JA, Blin P, Kloss S, Neugebauer RS, Platt RW, Potteg\u00e5rd A, et al. High-dimensional propensity scores for empirical covariate selection in secondary database studies: planning, implementation, and reporting. Pharmacoepidemiol Drug Saf. 2023;32(2):93\u2013106.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2545_CR47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/CLEP.S286572","volume":"13","author":"PC Lee","year":"2021","unstructured":"Lee PC, Kao FY, Liang FW, Lee YC, Li ST, Lu TH. Existing data sources in clinical epidemiology: the Taiwan National Health Insurance Laboratory Databases. Clin Epidemiol. 2021;13:175\u201381.","journal-title":"Clin Epidemiol"},{"key":"2545_CR48","unstructured":"National Health Insurance Administration. COPD pay-for-performance program [Chinese]. https:\/\/www.nhi.gov.tw\/Content_List.aspx?n=DDB1A5E178B7D09D&topn=5FE8C9FEAE863B46. Accessed 26 Feb 2023."},{"key":"2545_CR49","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1002\/sim.8355","volume":"38","author":"E Granger","year":"2019","unstructured":"Granger E, Sergeant JC, Lunt M. Avoiding pitfalls when combining multiple imputation and propensity scores. Stat Med. 2019;38:5120\u201332.","journal-title":"Stat Med"},{"key":"2545_CR50","unstructured":"SAS Institute Inc. SAS\/STAT\u00ae 14.1 User\u2019s Guide The MI Procedure. https:\/\/support.sas.com\/documentation\/onlinedoc\/stat\/141\/mi.pdf. Accessed 26 Feb 2023."},{"key":"2545_CR51","unstructured":"SAS Institute Inc. SAS\/STAT\u00ae 13.1 User\u2019s Guide The MIANALYZE Procedure. https:\/\/support.sas.com\/documentation\/onlinedoc\/stat\/131\/mianalyze.pdf. Accessed 26 Feb 2023."},{"issue":"7","key":"2545_CR52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/pds.2256","volume":"21","author":"JA Rassen","year":"2012","unstructured":"Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated n a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012;21(7):697\u2013709.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"2545_CR53","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/aje\/kwy049","volume":"187","author":"SV Wang","year":"2018","unstructured":"Wang SV, Jin Y, Fireman B, Gruber S, He M, Wyss R, et al. Relative performance of propensity score matching strategies for subgroup analyses. Am J Epidemiol. 2018;187(8):1799\u2013807.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2545_CR54","doi-asserted-by":"crossref","first-page":"2202208","DOI":"10.1183\/13993003.02208-2022","volume":"61","author":"P Almagro","year":"2023","unstructured":"Almagro P, Martinez-Camblor P. Comment on: combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. Eur Respir J. 2023;61(3):2202208.","journal-title":"Eur Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02545-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T21:27:54Z","timestamp":1700602074000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02545-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2545"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02545-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]},"assertion":[{"value":"14 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The National Yang-Ming Chiao Tung University Research Ethics Committee approved the study. Informed consent was waived given the retrospective nature of the study and the analysis of anonymous data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"239"}}